Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/75042
Campo DC Valoridioma
dc.contributor.authorOjeda, Soledaden_US
dc.contributor.authorPan, Manuelen_US
dc.contributor.authorMartin, Pedroen_US
dc.contributor.authorMazuelos, Franciscoen_US
dc.contributor.authorSuarez de Lezo, Javieren_US
dc.contributor.authorRomero, Miguelen_US
dc.contributor.authorSegura, Joseen_US
dc.contributor.authorPavlovic, Djordjeen_US
dc.contributor.authorMedina, Alfonsoen_US
dc.contributor.authorSuarez de Lezo, Joseen_US
dc.date.accessioned2020-10-27T13:38:00Z-
dc.date.available2020-10-27T13:38:00Z-
dc.date.issued2014en_US
dc.identifier.issn1936-8798en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/75042-
dc.description.abstractObjectives The goal of this study was to assess the immediate and long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) in an unprotected distal left main coronary artery (UDLM).Background PCI for UDLM-ISR can be complex. Limited information is available on procedural and clinical outcomes. Methods Between May 2002 and February 2011, UDLM-ISR after drug-eluting stent implantation was observed in 79 of 1,102 patients (7%). Seventy-five were treated by repeat PCI using a simple approach (balloon/in-stent implantation) or a complex strategy (additional stent/double-stenting technique). A diagnosis of mild or severe restenosis was considered depending on the number of bifurcation segments affected (1 vs. >1). Major adverse cardiac events (MACE) were defined as cardiac death, target lesion revascularization, and myocardial infarction.Results ISR treatment was performed using a simple approach in 44 (58%) patients, and using a complex strategy in 31 (42%). After 46 +/- 26 months, the MACE rate was 22%. Patients treated with a simple approach had a lower incidence of MACE at follow-up compared with patients treated with a complex strategy, regardless of the restenosis extent (mild restenosis: 93% vs. 67%, p < 0.05; severe: 70% vs. 23%, p < 0.05). On Cox regression analysis, diabetes was the only predictor of MACE (hazard ratio [HR]: 4.94; 95% confidence interval [CI]: 1.03 to 23.70; p < 0.05), whereas a simple strategy for ISR treatment was associated with lower risk (HR: 0.25; 95% CI: 0.08 to 0.79; p = 0.02).Conclusions PCI for UDLM-ISR is safe and feasible, with a high rate of procedural success and an acceptable long-term MACE rate. A simple strategy, when applicable, appears to be a good treatment option, associated with a lower event rate at follow-up. (C) 2014 by the American College of Cardiology Foundationen_US
dc.languageengen_US
dc.relation.ispartofJACC: Cardiovascular Interventionsen_US
dc.sourceJacc-Cardiovascular Interventions [ISSN 1936-8798], v. 7 (2), p. 212-221, (Febrero 2014)en_US
dc.subject320501 Cardiologíaen_US
dc.subject320704 Patología cardiovascularen_US
dc.subject321307 Cirugía del corazónen_US
dc.subject.otherCoronary-Artery-Diseaseen_US
dc.subject.otherDrug-Eluting Stenten_US
dc.subject.otherBypass-Surgeryen_US
dc.subject.otherBifurcation Lesionsen_US
dc.subject.otherInterventionen_US
dc.subject.otherStenosisen_US
dc.subject.otherImplantationen_US
dc.subject.otherAngioplastyen_US
dc.subject.otherPredictorsen_US
dc.subject.otherCardiologyen_US
dc.subject.otherBifurcation Lesionen_US
dc.subject.otherDrug-Eluting Stent(S)en_US
dc.subject.otherLeft Mainen_US
dc.subject.otherRestenosisen_US
dc.titleImmediate Results and Long-Term Clinical Outcome of Patients With Unprotected Distal Left Main Restenosis The CORPAL Registry (Cordoba and Las Palmas)en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jcin.2013.06.017en_US
dc.identifier.scopus84894343234-
dc.identifier.isi000331719900023-
dc.contributor.authorscopusid8654250900-
dc.contributor.authorscopusid7202544866-
dc.contributor.authorscopusid7406037925-
dc.contributor.authorscopusid24450657100-
dc.contributor.authorscopusid16067353500-
dc.contributor.authorscopusid7202430759-
dc.contributor.authorscopusid55415591100-
dc.contributor.authorscopusid7005198171-
dc.contributor.authorscopusid7202723590-
dc.contributor.authorscopusid7006785516-
dc.identifier.eissn1876-7605-
dc.description.lastpage221en_US
dc.identifier.issue2-
dc.description.firstpage212en_US
dc.relation.volume7en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid343824-
dc.contributor.daisngid77557-
dc.contributor.daisngid1673863-
dc.contributor.daisngid452208-
dc.contributor.daisngid67522-
dc.contributor.daisngid156230-
dc.contributor.daisngid1825688-
dc.contributor.daisngid831427-
dc.contributor.daisngid74576-
dc.contributor.daisngid476437-
dc.description.numberofpages10en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Ojeda, S-
dc.contributor.wosstandardWOS:Pan, M-
dc.contributor.wosstandardWOS:Martin, P-
dc.contributor.wosstandardWOS:Mazuelos, F-
dc.contributor.wosstandardWOS:de Lezo, JS-
dc.contributor.wosstandardWOS:Romero, M-
dc.contributor.wosstandardWOS:Segura, J-
dc.contributor.wosstandardWOS:Pavlovic, D-
dc.contributor.wosstandardWOS:Medina, A-
dc.contributor.wosstandardWOS:de Lezo, JS-
dc.date.coverdateFebrero 2014en_US
dc.identifier.ulpgcen_US
dc.description.sjr5,249
dc.description.jcr7,345
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Morfología-
crisitem.author.orcid0000-0002-2378-3242-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameMartín Rodríguez, Patricia-
Colección:Artículos
miniatura
Adobe PDF (1,19 MB)
Vista resumida

Citas SCOPUSTM   

16
actualizado el 30-mar-2025

Citas de WEB OF SCIENCETM
Citations

14
actualizado el 30-mar-2025

Visitas

81
actualizado el 14-dic-2024

Descargas

193
actualizado el 14-dic-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.